Bristol-Myers Squibb to Buy Celgene in $74 Billion Pharma Deal

Bristol-Myers Squibb to Buy Celgene in $74 Billion Pharma Deal

Assessment

Interactive Video

Business

University

Hard

Created by

Quizizz Content

FREE Resource

Bristol Myers Squibb is acquiring Celgene for $74 billion in a cash and stock deal. The acquisition, focused on cancer drugs like REVLIMID, comes amid market skepticism and follows an analyst call doubting large pharma deals. Investors are concerned about financing terms and regulatory approvals. Despite skepticism, this early-year mega deal suggests potential for more activity in the sector.

Read more

5 questions

Show all answers

1.

OPEN ENDED QUESTION

3 mins • 1 pt

What was the total value of the deal between Bristol Myers Squibb and Celgene?

Evaluate responses using AI:

OFF

2.

OPEN ENDED QUESTION

3 mins • 1 pt

What was the main reason for Bristol Myers Squibb to acquire Celgene according to the text?

Evaluate responses using AI:

OFF

3.

OPEN ENDED QUESTION

3 mins • 1 pt

What concerns did investors have regarding the financing of the acquisition?

Evaluate responses using AI:

OFF

4.

OPEN ENDED QUESTION

3 mins • 1 pt

What regulatory challenges might Bristol Myers Squibb face in completing the acquisition?

Evaluate responses using AI:

OFF

5.

OPEN ENDED QUESTION

3 mins • 1 pt

What skepticism existed in the market regarding mega pharma deals at the time of the acquisition?

Evaluate responses using AI:

OFF